Diego Jiménez

Dr. Diego Jiménez

PhD student at University of Turin
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
DJDiego Jiménez
Diego Jiménez
VPVasanthanathan Poongavanam
Vasanthanathan Poongavanam
JKJan Kihlberg
Jan Kihlberg

25 April 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
DJDiego Jiménez
Diego Jiménez
MSMatteo Rossi Sebastiano
Matteo Rossi Sebastiano
MVMaura Vallaro
Maura Vallaro
VMValentina Mileo
Valentina Mileo
DPDaniela Pizzirani
Daniela Pizzirani
Giulia CaronGiulia Caron
Giulia Caron
Solubility optimization is a crucial step to obtaining oral PROTACs. Here we measured the thermodynamic solubilities (log S) of 21 commercial PROTACs. Next, we measured BRlogD and log kwIAM (lipophilicity), EPSA, and Δ log kwIAM (polarity) and showed that lipophilicity plays a major role in governing log S, but a contribution of polarity cannot be neglected. Two-/three-dimensional descriptors calculated on conformers arising from conformational sampling and steered molecular dynamics failed in modeling solubility. Infographic tools were used to identify a privileged region of soluble PROTACs in a chemical space defined by BRlogD, log kwIAM and topological polar surface area, while machine learning provided a log S classification model. Finally, for three pairs of PROTACs we measured the solubility, lipophilicity, and polarity of the building blocks and identified the limits of estimating PROTAC solubility from the synthetic components. Overall, this paper provides promising guidelines for optimizing PROTAC solubility in early drug discovery programs.

25 July 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
DJDiego Jiménez
Diego Jiménez
MVMaura Vallaro
Maura Vallaro
MSMatteo Rossi Sebastiano
Matteo Rossi Sebastiano
GAGiulia Apprato
Giulia Apprato
GDGiulia D’aGostini
Giulia D’aGostini
Giulia CaronGiulia Caron
Giulia Caron
New chemical modalities in drug discovery include molecules belonging to the bRo5 chemical space. Because of their complex and flexible structure, bRo5 compounds often suffer from a poor solubility/permeability profile. Chameleonicity describes the capacity of a molecule to adapt to the environment through conformational changes; the design of molecular chameleons is a medicinal chemistry strategy simultaneously optimizing solubility and permeability. A default method to quantify chameleonicity in early drug discovery is still missing. Here we introduce Chamelogk, an automated, fast, and cheap chromatographic descriptor of chameleonicity. Moreover, we report measurements for 55 Ro5 and bRo5 compounds and validate our method with literature data. Then, selected case studies (macrocycles, nonmacrocyclic compounds, and PROTACs) are used to illustrate the application of Chamelogk in combination with lipophilicity (BRlogD) and polarity (Δ log kwIAM) descriptors. Overall, we show how Chamelogk deserves being included in property-based drug discovery strategies to design oral bioavailable bRo5 compounds.

28 January 2021 in Molecules
Verified
Journal Article
Open access
PDF file
GEGiuseppe Ermondi
Giuseppe Ermondi
DJDiego Jiménez
Diego Jiménez
Giulia CaronGiulia Caron
Giulia Caron
Targeted protein degradation by PROTACs has emerged as a new modality for the knockdown of a range of proteins, and, more recently, it has become increasingly clear that the PROTAC chemical space requires characterization through a pool of ad hoc physicochemical descriptors. In this study, a new database named PROTAC-DB that provides extensive information about PROTACs and building blocks was used to obtain the 2D chemical structures of about 1600 PROTACs, 60 E3 ligands, 800 linkers, and 202 warheads. For every structure, we calculated a pool of seven 2D descriptors carefully identified as informative for large and flexible structures. For comparison purposes, the same procedure was applied to a dataset of about 50 bRo5 approved drugs reported in the literature. Correlation matrices, PCAs, box plots, and other graphical tools were used to define and understand the chemical space covered by PROTACs and building blocks in relation to other compounds. Results show that linkers have different properties than E3 ligands and warheads. Polar descriptors additivity is not respected when passing from building blocks to degraders. Moreover, a very preliminary analysis based on three PROTACs with high, intermediate, and low permeability showed how the most permeable compounds seem to occupy a region closer to bRo5 drugs and, thus, exhibit different properties than impermeable compounds. Finally, a second database, PROTACpedia, was used to discuss the relevance of physicochemical descriptors on degradation activity.

8 June 2021 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
GEGiuseppe Ermondi
Giuseppe Ermondi
DJDiego Jiménez
Diego Jiménez
MSMatteo Rossi Sebastiano
Matteo Rossi Sebastiano
Giulia CaronGiulia Caron
Giulia Caron
To obtain new oral drugs in the beyond rule of five space, PROTACs among others, molecular properties should be optimized in early drug discovery. Degraders call for design strategies which focus on intramolecular interaction and chameleonicity. In parallel, tailored revalidation of permeability assessment and prediction methods becomes fundamental in this innovative chemical space.

29 June 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DJDiego Jiménez
Diego Jiménez
MSMatteo Rossi Sebastiano
Matteo Rossi Sebastiano
MVMaura Vallaro
Maura Vallaro
GEGiuseppe Ermondi
Giuseppe Ermondi
Giulia CaronGiulia Caron
Giulia Caron